Discovery by virtual screening of ethionamide boosters for tuberculosis treatment
Tuberculosis remains the world’s deadliest communicable bacterial disease with an unacceptably high death rate. In 2013 an estimated 1.5 million people died as a direct result of TB, and nine million new cases were reported. Multi-drug resistant (MDR) and extensively drug-resistant (XDR) tuberculosi...
Main Author: | Tatum, Natalie Joan |
---|---|
Published: |
Durham University
2015
|
Subjects: | |
Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.676051 |
Similar Items
-
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
by: Joana Costa-Gouveia, et al.
Published: (2017-07-01) -
Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
by: Joana Costa-Gouveia, et al.
Published: (2018-05-01) -
Virtual cocrystal screening
by: Grecu, T.
Published: (2014) -
Ethionamide pharmacokinetics in multidrugresistant tuberculosis patients with and without HIVinfection
by: Ezeukwu, Ifeoma Patricia
Published: (2018) -
Cyclic di-GMP regulates Mycobacterium tuberculosis resistance to ethionamide
by: Hai-Nan Zhang, et al.
Published: (2017-07-01)